Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Milan – page 204

2 864 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Milan at a glance
2 864
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 864 trials in Milan

Open in trial search

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Small cell lung cancer extensive stage

Not recruiting

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on AZD2693 for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis and PNPLA3 Genetic Marker

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Psoriasis

Not recruiting

Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Novartis Pharma AG

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of Teprotumumab for Patients with Thyroid Eye Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Acute myeloid leukaemia

Not recruiting

Study of venetoclax and azacitidine treatment in adults with NPM1-mutated acute myeloid leukemia who experience molecular relapse or disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Breast cancer metastatic

Not recruiting

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Milan

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.

  • Metastatic Colorectal Cancer Treatment
  • Breast Cancer Prevention Strategies
  • Advanced Solid Malignancies

Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.

02 Neurological Disorders

Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.

  • Frontotemporal Dementia
  • Parkinson's Disease
  • Migraine Treatment

Focus on developing targeted therapies and understanding disease mechanisms.

03 Immunology and Infectious Diseases

Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.

  • Immune Thrombocytopenia
  • RSV Prevention
  • HIV Prevention

Emphasis on developing novel preventive strategies and therapeutic solutions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.